文献速递骨软组织肉瘤与黑色素瘤

超声随访未提高早期黑色素瘤患者生存率:一项对比队列研究

Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study.
PubMed 文献 · Eur J Cancer · 2017-09-08

该研究比较了巴塞罗那临床随访队列与都灵超声随访队列中IB-IIA期黑色素瘤患者的预后,共纳入1149例患者。结论认为基于超声的随访并未提高IB-IIA期黑色素瘤患者的生存。

要点

  • 两组无病间期、无远处转移生存、无淋巴结转移生存和黑色素瘤特异性生存均无差异。
  • 基于超声的随访未提高IB-IIA期黑色素瘤患者的生存。

核心结论

  • 基于超声的随访未提高IB-IIA期黑色素瘤患者的生存。

研究设计与样本

  • 分析两个前瞻性收集的IB-IIA期黑色素瘤患者队列,分别来自巴塞罗那(临床随访,C-FU)和都灵(超声随访,US-FU)两个三级转诊中心。
  • 共纳入1149例AJCC IB-IIA期患者,其中C-FU组554例(48%),US-FU组595例(52%)。
  • 中位年龄53.8岁(IQR 41.5-65.2),中位随访时间4.14年(IQR 1.2-7.6)。

主要发现

  • 随访期间,C-FU组69例(12.5%)和US-FU组72例(12.1%)出现疾病进展。
  • 首次转移部位的中位至复发时间:皮肤转移2.11年(IQR 1.14-4.04),淋巴结转移1.32年(IQR 0.57-3.29),远处转移2.84年(IQR 1.32-4.60)。
  • 两个队列间无病间期、无远处转移生存、无淋巴结转移生存和黑色素瘤特异性生存均未发现差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Different protocols have been used to follow up melanoma patients in stage I-II. However, there is no consensus on the complementary tests that should be requested or the appropriate intervals between visits. Our aim is to compare an ultrasound-based follow-up with a clinical follow-up. PATIENTS AND METHODS: Analysis of two prospectively collected cohorts of melanoma patients in stage IB-IIA from two tertiary referral centres in Barcelona (clinical-based follow-up [C-FU]) and Turin (ultrasound-based follow-up [US-FU]). Kaplan-Meier curves were used to evaluate distant metastases-free survival (DMFS), disease-free interval (DFI), nodal metastases-free survival (NMFS) and melanoma-specific survival (MSS). RESULTS: A total of 1149 patients in the American Joint Committee on Cancer stage IB and IIA were included in this study, of which 554 subjects (48%) were enrolled for a C-FU, and 595 patients (52%) received a protocolised US-FU. The median age was 53.8 years (interquartile range [IQR] 41.5-65.2) with a median follow-up time of 4.14 years (IQR 1.2-7.6). During follow-up, 69 patients (12.5%) in C-FU and 72 patients (12.1%) in US-FU developed disease progression. Median time to relapse for the first metastatic site was 2.11 years (IQR 1.14-4.04) for skin metastases, 1.32 (IQR 0.57-3.29) for lymph node metastases and 2.84 (IQR 1.32-4.60) for distant metastases. The pattern of progression and the total proportion of metastases were not significantly different (P = .44) in the two centres. No difference in DFI, DMFS, NMFS and MSS was found between the two cohorts. CONCLUSION: Ultrasound-based follow-up does not increase the survival of melanoma patients in stage IB-IIA.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ribero S, Podlipnik S, Osella-Abate S, et al. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study. Eur J Cancer. 2017. PMID: 28888850. doi:10.1016/j.ejca.2017.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。